AQR rolls out multi-strategy alternatives fund
AQR Apex Ucits fund will invest in a range of lowly correlated sub-strategies
HEAD-TO-HEAD: Axa Framlington Biotech vs Polar Capital Healthcare Opportunities
In this week’s Head-to-Head, Gavin Haynes, managing director at Whitechurch Securities, matches up two medical heavyweights – Axa Framlington Biotech and Polar Capital Healthcare Opportunities.
